Price Transparency for Primary Care Office Visits and Routine Tests: Results From a 2016 Audit Study

Anchita Batra¹ and Molly Candon, PhD¹

Abstract
Introduction: Price transparency is a central component of the shift from volume to value in healthcare delivery. Price transparency in primary care, the most common point of contact with the healthcare system for patients in the U.S., has not been widely studied.

Methods: Using an audit study across 10 states in 2016, we examined the characteristics of primary care practices that were able to provide price information for office visits and routine tests.

Results: Most primary care practices were able to disclose some price information for office visits and routine tests. Results indicate that larger, integrated primary care practices in urban areas and in areas with a higher percentage of minority residents were less likely to provide prices than smaller, standalone practices.

Conclusion: These findings suggest that future efforts to increase price transparency in primary care should be tailored to practice characteristics, including practice location and whether the practice is embedded in an integrated health system.

Keywords
price transparency, primary care, secret shopper study, audit study

Highlights
What do we Already Know About this Topic?
An important element of value-based healthcare is price transparency, which has been historically lacking despite rapidly increasing healthcare prices in the U.S. To date, few policy efforts for price transparency have focused on primary care.

How does Your Research Contribute to the Field?
This study uses audit data from thousands of primary care practices in order to measure rates of price transparency in primary care. We build on prior literature in at least 3 ways: first, we provide a more up-to-date measure of price transparency for primary care office visits by using data collected after the implementation of the Affordable Care Act (ACA); second, we measure price transparency rates for routine tests in addition to office visits; and third, we consider the role of practice characteristics not previously explored, including whether the practice is part of an integrated health system.

What Are Your Research’s Implications Toward Theory, Practice, or Policy?
As efforts toward price transparency continue, it is important to understand which practices are more likely to provide prices to patients. Our findings—particularly that larger, integrated primary care practices are less able to provide prices compared
to smaller, standalone practices—suggest that price transparency policies cannot be one-size-fits-all and may need to be adapted based on practice characteristics.

Introduction

The shift from volume to value is upending healthcare delivery in the United States. An important component of value-based care is price transparency, which has been historically lacking in the U.S. despite rapidly increasing healthcare prices. In fact, healthcare prices have been rising faster than the consumer price index for decades.

Over the last decade, policymakers have increased their focus on price transparency, in part due to the proliferation of high-deductible health plans, health savings accounts, and a more “consumer-driven marketplace” in healthcare. Examples include a 2019 Executive Order, which requires hospitals to disclose prices for selected procedures, as well as state-level initiatives in Massachusetts, Virginia, New Hampshire, and Minnesota to increase price transparency in hospitals. More recently, the Centers for Medicare and Medicaid Services (CMS) introduced a Hospital Price Transparency Rule. Despite some pushback, President Biden supported CMS in their efforts to reduce hospital costs and also to improve transparency of prescription drug prices.

However, these policy changes have been limited in scope and “gaps remain in the accessibility and usefulness of the information.” For example, the aforementioned policy efforts targeting price transparency have largely focused on hospitals, which account for 31% of national healthcare expenditures. Less has been done to ameliorate price transparency in primary care, which comprises over half of all healthcare visits and remains the most common point of contact with the healthcare system. Existing research indicates that many primary care providers are unable to disclose price information to patients despite the “chief responsibility” they bear in discussing the affordability of treatment options with patients. In fact, one milestone of the Accreditation Council for Graduate Medical Education in Internal Medicine is to identify “forces that impact the cost of health care, and advocate for, and practice cost-effective care.”

Moreover, it is unclear how patients experience price transparency. One way that researchers can address this is to use patient-centric methodologies, such as secret shopper and audit studies. A notable example of this approach is from Saloner and colleagues, who measured price transparency rates in primary care and found that it was associated with several factors, including whether the practice was a federally qualified health center (FQHC). Their audit study used data that was collected during the implementation of the Patient Protection and Affordable Care Act (ACA) in 2014, which increased funding for FQHCs and temporarily increased Medicaid reimbursement to Medicare levels for primary care providers. This made it difficult to distinguish between changes brought forth by the ACA and changes related to the broader shift to value-based healthcare delivery models, like the increase in patient-centered medical homes.

In this study, we measure price transparency in primary care practices across 10 states using an audit study from 2016, building on prior literature in at least 3 ways. First, we use data that was collected after the implementation of the ACA. Second, we measure price transparency for routine tests in addition to office visits. Third, we consider the role of practice characteristics not previously explored in this context, including whether the practice is part of an integrated health system and whether the practice offers other consumer-driven amenities, like after-hours appointments.

Methods

Data Collection

We used audit data collected in 2016 from 10 states: Arkansas, Georgia, Illinois, Iowa, Massachusetts, Montana, New Jersey, Oregon, Pennsylvania, and Texas. Data collection and the study protocol were approved by the Institutional Review Board at the University of Pennsylvania and are described elsewhere. The requirement for informed consent was waived because the research team was interested in the healthcare system overall, and the confidentiality of individual practices was protected. The study’s sponsor, the Robert Wood Johnson Foundation, was not involved in the design or conduct of this study, the preparation of this manuscript, or the decision to submit this manuscript for publication.

The sample frame of primary care practices was randomly selected from the SK&A Office-Based Physician Database, which has been increasingly used for research purposes, with studies finding that it can provide reasonably accurate and up-to-date information compared to other administrative datasets. Eligible offices had to have at least 1 primary care physician (PCP) who served working-age adults, and were in-network by insurance type, which was determined using a survey conducted prior to the audit study. Practices could receive multiple calls from callers with different insurance types.

Trained callers were randomized to insurance types and asked to simulate new patients. In their calls, they requested the earliest appointment available with a randomly selected PCP within the practice; callers accepted an appointment with advanced practitioners, that is, nurse practitioners and physician assistants, when offered. To be considered an appointment, the scheduler was required to provide a specific date and time. All appointments were canceled at the end of the call or shortly after the call took place. Prices were only
requested for scheduled appointments for those callers with private insurance (either employer-based or from the ACA health insurance exchanges) and callers who claimed to be self-pay.

Overall, 5988 calls were included in the office visit analysis, 5205 in the routine test analysis, and 1809 in the average price of an office visit analysis. We excluded 484 calls because the caller could not get past appointment restrictions, such as requiring an insurance number, 1230 calls because of vague appointment availability, which occurred if the scheduler could not give a precise date or time, and another 1843 calls because the caller could not schedule an appointment. Finally, 630 calls were excluded because practice characteristics in the SK&A database were missing.

Measures

We examined 2 outcomes: a binary variable indicating an inability to get a specific price or a range of prices for an office visit, and a binary variable indicating an inability to receive prices for routine tests that may be conducted at the visit. We also measured office visit prices for those calls in which a specific price, rather than a range of prices, was provided. This information was collected by trained callers using the following prompts: Were you able to find out the basic price of your visit? How much will the visit cost? If the doctors ordered any tests, could you be told the price before you have them?

Statistical Analyses

For each outcome, we estimated a linear probability model with the following practice and county characteristics: practice size, which was defined as the number of PCPs and the number of advanced practitioners; whether the practice provided after-hours or walk-in appointments; whether the practice was part of an integrated health system; whether the practice was an FQHC; and county-level estimates of income, race/ethnicity, and urbanicity. We included state fixed effects and clustered standard errors at the county-level.

Results

The study sample used for the office visit outcome included 5988 calls made to primary care practices with an average of ~3 physicians and ~1 advanced practitioner (Table 1). Roughly a third of calls were made to practices that offered flexible hours or were part of an integrated health system. More calls were made to practices located in urban neighborhoods and in areas with a majority of white residents. Fewer calls were placed in rural areas and in areas with a majority of Black and Hispanic residents.

Most practices were able to disclose some price information for office visits (Figure 1), whereas 92% of calls were told they could obtain prices for routine tests (Figure 2). The precision of price information varied, however. For instance, only 30% of calls were able to get the exact price of an office visit.

Across the 10 states and 3 insurance types, price transparency rates varied substantially. The estimated price of an office visit varied as well. The average price of an office visit was $137, with the lowest prices found in New Jersey ($117) and the highest price found in Massachusetts ($182) (Table 2). On average, callers with insurance purchased on ACA Health Insurance Exchanges were quoted lower prices ($125) than callers with commercial (i.e., employer-sponsored) insurance ($139) and callers who had no insurance (i.e., self-pay) ($149).

Linear probability models indicated that practices with more PCPs ($P < .001), more advanced practitioners ($P = .001), and

| Table 1. Summary Statistics. |
|-------------------------------|
| Practice characteristics       |
| # Primary care physicians      | 2.78  | 3.86 |
| # Advanced practitioners       | 1.10  | 1.84 |
| Have after hours               | 37.16%| 48.33|
| Have walk-in hours             | 34.77%| 47.63|
| Integrated health system       | 32.48%| 46.83|
| Accountable care organization  | 34.82%| 47.64|
| Federally qualified health center | 5.59%| 22.98|
| County characteristics         |
| Median household income (thousands) | 61.34| 16.21|
| %Black                         | 12.25%| 13.74|
| %Hispanic                      | 13.66%| 14.19|
| %Urban                         | 79.16%| 25.48|
| Insurance type                 |
| Commercial                     | 47.56%| n = 2848|
| None                           | 15.65%| n = 937 |
| ACA Health Insurance Exchange  | 36.79%| n = 2203|
| State                          |
| Arkansas                       | 8.98% | n = 538 |
| Georgia                        | 11.86% | n = 710 |
| Indiana                        | 10.99% | n = 658 |
| Illinois                       | 11.62% | n = 696 |
| Massachusetts                  | 7.97% | n = 477 |
| Montana                        | 4.61% | n = 276 |
| New Jersey                     | 12.98% | n = 777 |
| Oregon                         | 7.72% | n = 462 |
| Pennsylvania                   | 11.32% | n = 678 |
| Texas                          | 11.96% | n = 716 |
| Number of calls                | 5988  |      |

Sources. Authors’ calculations.
Notes. Summary statistics are based on calls used in the office visit analysis.
Figure 1. Ability to Obtain Prices for Office Visits Overall, by Insurance Type, and by State.
SOURCE: Authors’ calculations.
NOTES: Error bars denote 95% confidence intervals. HIX refers to insurance bought on the ACA Health Insurance Exchange.
Figure 2. Ability to Obtain Prices for Routine Tests Overall, by Insurance Type, and by State.

SOURCE: Authors’ calculations.

NOTES: Error bars denote 95% confidence intervals. HIX refers to insurance bought on the ACA Health Insurance Exchange.
Table 2. Average Cost of an Office Visit by Insurance Type and State.

| Insurance type                      | Mean   | Standard Deviation |
|-------------------------------------|--------|--------------------|
| Commercial                          | $139.31| $7.12              |
| None                                | $149.11| $8.47              |
| ACA Health Insurance Exchange       | $124.76| $6.41              |
| Arkansas                            | $127.40| $14.45             |
| Georgia                             | $134.77| $9.80              |
| Indiana                             | $153.75| $9.36              |
| Illinois                            | $139.04| $11.14             |
| Massachusetts                        | $181.91| $23.22             |
| Montana                             | $159.42| $16.89             |
| New Jersey                          | $117.29| $9.06              |
| Oregon                              | $163.32| $21.83             |
| Pennsylvania                        | $128.56| $10.82             |
| Texas                               | $122.63| $13.73             |
| Number of calls                     | 1809               |

Sources. Authors’ calculations.
Notes. Average total costs were calculated for calls where a specific price, rather than an approximate/range of prices, was given.

that were an FQHC (P < .001) were more likely to be unable to provide prices for an office visit (Table 3). Calls placed in urban areas (P = .035), in areas with more Hispanic residents (P = .018), and in areas with more Black residents (P = .020) were also less likely to receive a price for an office visit.

Fewer practice characteristics were correlated with the ability to provide prices for routine tests, although we did find that practices without walk-in hours were more likely to provide prices for routine tests (P = .006). Calls placed in areas with more Black residents (P = .005) and in areas with a higher median household income (P = .003) were less likely to receive prices for routine tests.

Discussion

In recent years, policymakers have engaged in a concerted effort to make healthcare prices more readily available for patients. However, these attempts have mostly focused on hospitals and prescription drugs. Given the large role that primary care plays in healthcare delivery and the continued proliferation of high-deductible health plans and health savings accounts, additional efforts toward price transparency in primary care may be warranted.

This study used audit data from 2016 to measure rates of price transparency and identify which practice and county-level characteristics were associated with price transparency. We found that nearly 40% of primary care practices were unable to disclose any price information for office visits, while fewer than 10% of practices were unable to disclose any price information for routine tests. Larger, integrated practices in urban areas and in areas with higher percentages of minorities were less likely to provide prices, while smaller, standalone practices were more likely to provide prices.

Another notable finding was the relatively low rates of price transparency for office visits at FQHCs, which aligns with Saloner et al. (2017). Federally qualified health centers tend to target uninsured and underinsured populations and often use sliding-scale fees that require callers to specify their income levels, which may explain their inability to provide prices to callers.27

Our results beg the question of why smaller practices and practices without access to resources available in integrated health systems were more likely to provide prices to callers. One potential reason is that these practices cater to fewer patients, who may be more likely to have longstanding ties to the practice.28,29 Indeed, primary care practices in small towns often accompany “patients from the cradle to the grave.”30 Whether longer-term relationships can serve as an added incentive to provide more consumer-driven amenities to patients, such as price transparency, is unclear. Smaller, standalone practices may also have more capacity, which could afford them flexibility in their scheduling practices. This was supported by additional analyses, which found that practices able to provide a price tended to have lower wait times for an appointment (approximately 2 days shorter). In contrast, larger practices in integrated health systems may be less likely to provide prices given capacity concerns, as is indicated by longer wait times.

Another potential explanation is the role of centralized scheduling. Larger, integrated systems may be more likely to rely on a centralized scheduling system, which can increase scheduling efficiency across multiple practices.31-33 While centralized scheduling may increase efficiency, there are other trade-offs to consider. Because these systems cater to multiple practices and patient types, centralized schedulers may be less equipped to enact price transparency initiatives. Alternatively, it could be that the practices associated with integrated health systems are more likely to operate in concentrated markets (notably, increasing concentration throughout healthcare delivery has raised concerns of adverse consequences for both cost and quality).34,35

Centralized scheduling could not be explored directly in our analysis. Nor could we examine whether price transparency in primary care benefits patients or affects their perceptions of care.36 A 2007 study suggested that price transparency efforts, under certain conditions, could inadvertently increase prices and disadvantage low-income patients.37 Other studies have shown that few patients access price transparency tools and that these tools are unlikely to change key measures, such as aggregate healthcare spending.11 Yet additional research has shown that price-aware patients do change their decisions based on prices, and that price transparency may affect the bargaining process between providers and payers.38-40
As policymakers continue to focus on price transparency throughout healthcare delivery, it is important to understand how price transparency has changed over the years. Thus, a more up-to-date study of price transparency in primary care is needed, and could help identify the impact of recent policy initiatives. Potential mechanisms of price transparency, such as the role of centralized scheduling and the effects of market competition and concentration, warrant further study.

Limitations
This study has several limitations. First, calls were restricted to in-network offices accepting new, nonelderly patients across 10 states, covering roughly 25% of the U.S. population. Second, the cross-sectional study design can only identify associations between practice and county-level characteristics and price transparency rates. Third, we focus on prices from the patient’s perspective, which could involve insurance payments and/or out-of-pocket spending, rather than delve into the complexities surrounding healthcare accounting systems. Finally, while we controlled for median household income in our analyses, we did not directly examine the role of patients’ incomes or plan design. Price transparency may matter more to patients with lower incomes or with certain insurance types, such as high-deductible health plans.

Conclusion
The continued proliferation of consumer-driven healthcare, such as high-deductible health plans and health savings accounts, necessitates increased price transparency at all levels of healthcare, including primary care. This requires a better understanding of how prices in primary care are communicated to patients. Our results suggest that certain practices may be less likely to accommodate a demand for price transparency. Specifically, we found that larger, integrated primary care practices in urban areas and in areas with higher percentages of minorities were less transparent with prices compared to smaller, standalone practices. This suggests that policy approaches targeting price transparency may need to be catered based on practice characteristics such as location.
size, and whether the practice is embedded in an integrated health system.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Initial data collection was supported by the Robert Wood Johnson Foundation (#71100).

ORCID iDs
Anchita Batra  https://orcid.org/0000-0002-4322-3672
Molly Candon  https://orcid.org/0000-0001-8312-951X

References
1. Teisberg E, Wallace S, O’Hara O’Hara S. Defining and implementing value-based health care. Acad Med. 2020;95(5):682-685.
2. Miller BJ, Mandelberg MC, Griffith NC, Ehrenfeld JM. Price transparency: Empowering patient choice and promoting provider competition. J Med Syst. 2020;44(4):80. doi: 10.1007/s10916-020-01553-2.
3. Kurani N, Ortaliza J, Wager E, Fox L, Amin K. How has U.S. spending on healthcare changed over time? Peterson-KFF health system tracker. 2022.
4. Sinaiko AD, Chien AT, Rosenthal MB. The role of states in improving price transparency in health care. JAMA Intern Med. 2015;175(6):886-887. doi: 10.1001/jamainternmed.2015.0628.
5. Jenny HE, Jenny BE. A healthy dose of price transparency in US health care services. JAMA Surgery. 2020;155(7):544-545. doi: 10.1001/jamasurg.2020.0754.
6. Sinaiko AD, Makmor-Bakry M, Hatah E. Drug price trans- parency tool: Who uses it, and how they shop for care. Health Aff. 2016;35(4):662-670.
7. Sinaiko AD, Chien AT, Rosenthal MB. The role of states in improving price transparency in health care. JAMA Intern Med. 2015;175(6):886-887. doi: 10.1001/jamainternmed.2015.0628.
8. Centers for Medicare and Medicaid Services. Press release: Biden-Harris administration improves transparency and oversight of prescription drug and medical costs. CMS. 2021. Available at https://www.cms.gov/newsroom/press-releases/biden-harris-administration-improves-transparency-and-oversight-prescription-drug-and-medical-costs.
9. Sinaiko AD, Rosenthal MB. Examining a health care price transparency tool: Who uses it, and how they shop for care. Health Aff. 2016;35(4):662-670.
10. Centers for Medicare and Medicaid Services. Press release: CMS OPPS/ASC final rule increases price transparency, patient safety and access to quality care. CMS. 2021. Available at https://www.cms.gov/newsroom/press-releases/cms-oppasc-final-rule-increases-price-transparency-patient-safety-and-access-quality-care.
11. Sinaiko AD, Rosenthal MB. Examining a health care price transparency tool: Who uses it, and how they shop for care. Health Aff. 2016;35(4):662-670.
12. Centers for Medicare and Medicaid Services. Press release: CMS OPPS/ASC final rule increases price transparency, patient safety and access to quality care. CMS. 2021. Available at https://www.cms.gov/newsroom/press-releases/cms-oppasc-final-rule-increases-price-transparency-patient-safety-and-access-quality-care.
13. Liss S. Hospitals lose another attempt to stave off price transparency. HR Dive. 2020.
14. Health Affairs. National health spending In 2020. Health Aff. 2020;39(3):421-428. doi: 10.1377/hlthaff.2019.01430.
15. Frakt A, Mehrotra A. What type of price transparency do we need in health care? Ann Intern Med. 2019;170(8):561. doi: 10.7326/m19-0534.
16. Centers for Disease Control and Prevention. Ambulatory Care Facilities Final Rule Increases Price Transparency, Patient Safety, and Access to Quality Care. 2019. Available at https://www.federalregister.gov/documents/2019/06/27/2019-13945/improving-price-and-quality-transparency-in-american-healthcare-to-put-patients-first.
17. Schiavoni KH, Lehmann LS, Guan W, Rosenthal M, Sequist TD, Chien AT. How primary care physicians integrate price information into clinical decision-making. J Gen Intern Med. 2016;32(1):81-87. doi: 10.1007/s11606-016-3805-0.
18. Exploring the ACGME core competencies (part 1 of 7). NEJM Knowledge+. (2021, May 18). Retrieved February 8, 2022 from https://knowledgeplus.nejm.org/blog/exploring-acgme-core-competencies/
19. Kobayashi D, Goto R, Tsugawa Y. Impact of improved price transparency on patients’ demand of healthcare services. Soc Sci Med. 2019;235:112390. doi: 10.1016/j.socscimed.2019.112390.
20. French VA, Mattingly TL, Rangel AV, Shelton AU. Availability of ulipristal acetate: A secret shopper survey of pharmacies in a metropolitan area on emergency contraception. J Am Pharmace ut Assoc. 2019;59(6):832-835.
21. Kaboli PJ, Fihn SD. Waiting for care in veterans affairs health care facilities and elsewhere. JAMA Network Open. 2019;2(1):e180779.
22. Loomer L, Gandhi A, Geng F, Grabowski DC. Secret shopper data on private prices in the nursing home industry from 2008 to 2010. Med Care Res Rev. 2019;78(4):449-457. doi: 10.1177/1077558719879022.
23. Polsky D, Candon M, Saloner B, et al. Changes in primary care access between 2012 and 2016 for new patients with medicaid and private coverage. JAMA Intern Med. 2017;177(4):588-590. doi: 10.1001/jamainternmed.2016.9662.
24. Polsky D, Richards M, Bassey N, et al. Appointment availability after increases in medicaid payments for primary care. N Engl J Med. 2015;372(6):537-545. doi: 10.1056/nejmsa1413299.
25. Peikes D, Taylor EF, O’Malley AS, Rich EC. The changing landscape of primary care: Effects of the ACA and other efforts over the past decade. Health Aff. 2020;39(3):421-428. doi: 10.1377/hlthaff.2019.01430.
26. DesRoches CM, Barrett KA, Harvey BE, et al. The results are only as good as the sample: Assessing three national physician sampling frames. *J Gen Intern Med*. 2015;30(S3):595-601. doi: 10.1007/s11606-015-3380-9.

27. Saloner B, Cope LC, Hempstead K, Rhodes KV, Polsky D, Kenney GM. Price transparency in primary care: Can patients learn about costs when scheduling an appointment? *J Gen Intern Med*. 2017;32(7):815-821. doi:10.1007/s11606-017-4003-4.

28. Liaw WR, Jetty A, Pettersson SM, Peterson LE, Bazemore AW. Solo and small practices: A vital, diverse part of primary care. *Ann Fam Med*. 2016;14(1):8-15. doi:10.1370/afm.1839.

29. Porter S. Reducing hospital admissions: Small primary care practices Shine in national study. *Ann Fam Med*. 2016;12(6):578-579. doi:10.1370/afm.1715.

30. Pohontsch NJ, Hansen H, Schäfer I, Scherer M. General practitioners’ perception of being a doctor in urban vs. rural regions in Germany - A focus group study. *Fam Pract*. 2017;35(2):209-215. doi:10.1093/fampra/cmx083.

31. Davis Creech MD. Save money and reduce stress with centralized scheduling in healthcare. *Becker’s Hospital Review*. 2020. Available at https://www.beckershospitalreview.com/patient-experience/save-money-and-reduce-stress-with-centralized-scheduling-in-healthcare.html.

32. Institute of Medicine. *Transforming Health Care Scheduling and Access: Getting to Now*. Washington, DC: The National Academies Press; 2015. doi:10.17226/20220.

33. Gupta D, Denton B. Appointment scheduling in health care: Challenges and opportunities. *IEE Trans*. 2008;40(9):800-819. doi:10.1080/07408170802165880.

34. Fulton BD. Health care market concentration trends in the United States: Evidence and policy responses. *Health Aff*. 2017;36(9):1530-1538. doi:10.1377/hlthaff.2017.0556.

35. Gaynor M, Ho K, Town RJ. The industrial organization of health-care markets. *J Econ Lit*. 2015;53(2):235-284.

36. Li Miao L, Mattila AS. How and how much to reveal? The effects of price transparency on consumers’ price perceptions. *J Hospit Tourism Res*. 2007;31(4):530-545. doi:10.1177/1096348007302354.

37. Kyle MK, Ridley DB. Would greater transparency and uniformity of health care prices benefit poor patients? *Health Aff*. 2007;26(5):1384-1391. doi:10.1377/hlthaff.26.5.1384.

38. Zhang A, Prang K-H, Devlin N, Scott A, Kehler M. The impact of price transparency on consumers and providers: A scoping review. *Health Pol*. 2020;124(8):819-825. doi:10.1016/j.healthpol.2020.06.001.

39. Desai S, Hatfield LA, Hicks AL, Chernew ME, Mehrotra A. Association between availability of a price transparency tool and outpatient spending. *JAMA*. 2016;81(17):1874. doi:10.1001/jama.2016.4288.

40. Pauly MV, Burns LR. Price transparency for medical devices. *Health Aff*. 2008;27(6):1544-1553. doi:10.1377/hlthaff.27.6.1544.